(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 December 2009 (10.12.2009)

PCT

(10) International Publication Number
WO 2009/147438 A1

(51) International Patent Classification:
A61K 31/138 (2006.01) *A61K 31/53* (2006.01)
A61K 31/17 (2006.01) *A61P 35/00* (2006.01)
A61K 31/282 (2006.01) *A61K 31/185* (2006.01)
A61K 31/352 (2006.01) *A61K 45/06* (2006.01)
A61K 31/4535 (2006.01)

(21) International Application Number:
PCT/GB2009/050620

(22) International Filing Date:
4 June 2009 (04.06.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0810203.0 4 June 2008 (04.06.2008) GB

(71) Applicants *(for all designated States except US)*: **GW PHARMA LIMITED** [GB/GB]; Porton Down Science Park, Salisbury Wiltshire SP4 0JR (GB). **OTSUKA PHARMACEUTICAL CO. LIMITED** [JP/JP]; 2-9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 101-8535 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **VELASCO DIEZ, Guillermo** [ES/ES]; Departamento de Bioquimica y Biologia Molecular I, Facultad de Ciencias Quimicas, Universidad Complutense de Madrid, E-28040 Madrid (ES). **GUZMAN PASTOR, Manuel** [ES/ES]; Departamento de Bioquimica y Biologia Molecular I, Facultad de Ciencias Quimicas, Universidad Complutense de Madrid, E-28040 Madrid (ES). **LORENTE, Mar** [ES/ES]; Departamento de Bioquimica y Biologia Molecular I, Facultad de Ciencias Quimicas, Universidad Complutense de Madrid, E-28040 Madrid (ES). **TORRES, Sofia** [ES/ES]; Departamento de Bioquimica y Biologia Molecular I, Facultad de Ciencias Quimicas, Universidad Complutense de Madrid, E-28040 Madrid (ES).

(74) Agent: **HARRISON GODDARD FOOTE**; Orlando House, 11c Compstall Road, Marple Bridge, Stockport, Greater Manchester SK6 5HH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

WO 2009/147438 A1

(54) **Title**: CANNABINOIDS IN COMBINATION WITH NON -CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS)

(57) **Abstract**: The invention relates to the use of one or more cannabinoids, particularly THC and/ or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme(GBM).The non- cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.